Christopher Voigt, MD, Suzane Silbert, PHD, Raymond H. Widen, PHD, Joseph E. Marturano, PHD, Thomas J. Lowery, PHD, Deborah Ashcraft, BS, and George Pankey, M
Bacteremia represents a significant healthcare burden across the globe, leading to issues that are not only financial in nature, but also clinical, with high attributable morbidity and mortality rates. Current diagnostic methods for identifying bacteremia rely on positive blood cultures that often take days to provide results and also may be impacted by low accuracy, as the cultures are often times inhibited by the presence of antimicrobials.
This study aimed to evaluate the FDA-cleared T2Bacteria Panel’s performance and potential to impact patient care in the emergency department. Patients from two US-based hospitals were enrolled as part of this clinical study, which was prospective and noninterventional. Data from 137 emergency department patients were evaluated and the blood samples were matched in anatomic location and time of collection.